Unmet needs in the diagnosis and treatment of dyslipidemia in the primary care setting in Germany

Atherosclerosis

Volumn 190, Issue 2, 2007, Pages 397-407

  Bohler S ^a   Scharnagl, H ^b   Freisinger, F ^b   Stojakovic, T ^b   Glaesmer, H ^a   Klotsche, J ^a   Pieper, L ^a   Pittrow, D ^a   Kirch, W ^a   Schneider, H ^c   Stalla, G K ^c   Lehnert, H ^d,e   Zeiher, A M ^f   Silber, S ^g   Koch, U ^h   Ruf, G ⁱ   Marz W ^b   Wittchen, H U ^a,c  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

^e UNIVERSITY OF WARWICK   (United Kingdom)

^f GOETHE UNIVERSITY   (Germany)

^g Department of Medical Psychology ^*

^h UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

ⁱ PFIZER INC   (United States)

Author keywords

Cardiovascular risk; Coronary heart disease; Dyslipidemia; Lipid disorders; Prevalence; Risk factors

Indexed keywords

ANTILIPEMIC AGENT; BILE ACID SEQUESTRANT; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID DERIVATIVE; OMEGA 3 FATTY ACID;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; GERMANY; HEALTH CARE NEED; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK FACTOR;

EID: 33846116628     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.02.025     Document Type: Article

References (24)

1. Vasan R.S., et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med 142 6 (2005) 393-402
2. De Backer G., et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 10 4 (2003) S1-S10
3. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA, 2001. 285 (19): p. 2486-2497.
4. Williams B., et al. British hypertension society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 328 7440 (2004) 634-640
5. Grundy S.M., et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 110 2 (2004) 227-239
6. Pedersen T.R., et al. Design and baseline characteristics of the incremental decrease in end points through aggressive lipid lowering study. Am J Cardiol 94 6 (2004) 720-724
7. LaRosa J.C., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 14 (2005) 1425-1435
8. Waters D.D., et al. Treating to new targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?. Am J Cardiol 93 2 (2004) 154-158
9. EUROASPIRE I and II Group. European action on secondary prevention by intervention to reduce events. clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European action on secondary prevention by intervention to reduce events. Lancet 357 9261 (2001) 995-1001
10. Assmann G., et al. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROC AM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124 Suppl. (1996) S11-S20
11. Keil U., et al. Classical risk factors and their impact on incident non-fatal and fatal myocardial infarction and all-cause mortality in southern Germany. Results from the MONICA Augsburg cohort study 1984-1992. Monitoring trends and determinants in cardiovascular diseases. Eur Heart J 19 8 (1998) 1197-1207
12. Breckenkamp J., Laaser U., and Meyer S. The German cardiovascular prevention study: social gradient for the net effects in prevention of hypercholesterolemia. Z Kardiol 84 9 (1995) 694-699
13. Bernhardt R., et al. Incidence and mortality rates of myocardial infarction in Chinese workers aged 40-59 in relation to coronary risk factors. Results of a Chinese prospective study (Wuhan Study) in comparison to the Gottingen Risk Incidence and prevalence study (GRIPS). Klin Wochenschr 69 5 (1991) 201-212
14. Richter W.O., Sonnichsen A.C., and Schwandt P. Results and efficacy of public screening for hypercholesterolemia: the Bavarian cholesterol screening project. J Clin Epidemiol 48 11 (1995) 1307-1317
15. Jaross W., et al. Comparison of risk factors for coronary heart disease in Dresden and Munster. Results of the DRECAN (dresden cardiovascular risk and nutrition) study and the PROCAM (prospective cardiovascular munster) study. Eur J Epidemiol 10 3 (1994) 307-315
16. Schwandt P., Geiss H.C., and Haas G.M. Global cardiovascular risk in children and their families: the prevention education program (PEP), Nurnberg. Nutr Metab Cardiovasc Dis 11 Suppl. 5 (2001) 35-39
17. Wittchen H.U., et al. Cardiovascular risk factors in primary care: methods and baseline prevalence rates-the DETECT program. Curr Med Res Opin 21 4 (2005) 619-630
18. Böhler S., et al. Diabetes and cardiovascular risk evaluation and management in primary care: progress and unresolved issues-rationale for a nationwide primary care project in Germany. Exp Clin Endocrinol Diabetes 112 4 (2004) 157-170
19. Hense H.W., et al. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany-results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 24 10 (2003) 937-945
20. Stata, Stata Corp. Statistical software: release 8.0. College Station, TX: Stata Corporation. 2003.
21. Assmann G., Cullen P., and Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular munster (PROCAM) study. Circulation 105 3 (2002) 310-315
22. Cremer P., and Muche R. The Gottingen risk. Incidence and prevalence (GRIPS) study. Recommendations for the prevention of coronary heart disease. Ther Umsch 47 6 (1990) 482-491
23. von Eckardstein A., Schulte H., and Assmann G. Comparison of international recommendations for the recognition of asymptomatic high risk patients for a heart attack in Germany. Z Kardiol 94 1 (2005) 52-60
24. Sever P.S., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 9364 (2003) 1149-1158